Empliciti (Elotuzumab) A New Immunotherapy Cancer Treatment for Multiple Myeloma

http://youtu.be/4TwUveSjkAY Empliciti (Elotuzumab) is a promising new FDA approved immunotherapy treatment for multiple myeloma cancer, which is a blood cancer that occurs within the plasma cells. In this video, oncologist Dr. Stephen Lemon describes how this cancer drug works and what types of side effects it may cause. Visit http://www.oacancer.com/how-empliciti-elotuzumab-treats-multiple-myeloma/ to learn more about this treatment. Empliciti is approved with the combination of two other FDA approved cancer drugs - Revlimid (lenalidomide) and Decadron (dexamethasone) - for patients who have received one to three prior myeloma therapies. Empliciti belongs to a class of cancer drugs referred to as monoclonal antibodies, which are developed in a lab rather than by a person's immune system. These antibodies help to alert the patient's immune system to destroy the targeted cancer cells. Emplicti is developed by Bristol-Myers Squibb. Stephen Lemon MD is a medical oncologist with Oncology Associates, based in Omaha, and is not affiliated with Bristol-Myers Squibb. Visit http://www.oacancer.com to learn more about Oncology Associates and their approach to personalized cancer treatment.